Opendata, web and dolomites


Accelerating the commercialisation of a disruptive analytical technology which enables the biopharmaceutical industry to manufacture drugs faster, cheaper and with greater regulatory confidence

Total Cost €


EC-Contrib. €






Project "BIOSIM" data sheet

The following table provides information about the project.


Organization address
city: DUBLIN 2
postcode: V94
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website
 Total cost 2˙029˙325 €
 EC max contribution 2˙029˙325 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VALITACELL LTD IE (DUBLIN 2) coordinator 2˙029˙325.00


 Project objective

The global Biologic drug [including Vaccines] market exceeds €500 bn with an annual growth of 8%. Biopharmaceutical companies need to be able to produce these new biologic drugs faster and cheaper to meet the needs of patients, regulators and the governments and insurance companies who are paying for these high cost therapies. Valitacell is an Irish SME which currently supplies this market and is a validated supplier to a growing number of market leaders including GE Healthcare & MedImmune.

BIOSIM will accelerate the commercialisation of our ChemStress technology platform for this industry. Scientifically these tests measure a cell’s performance when exposed to small molecule chemicals which simulate the stresses that the cell will experience in the scaled-up manufacturing process. When applied together they can reduce the average Cell Line Development stage of drug manufacture from 16 to 6 months and reduce the average cost from €2.3million to €1.1 million.

BIOSIM will support: the demonstration of ChemStress at 4 leading biopharmaceutical manufacturing sites resulting in the generation of a customer endorsed value proposition; productise the ChemStress platform for the Biopharmmaceutical industry; refinement, scale-up and validation of the product manufacture; priming the sales & marketing for product launch. . ChemStress will realise €40m of end-user product sales and support 50 jobs in the 5 years following the project. ChemStress will provide EU Biomanufacturers with the opportunity to maintain their leadership position by implementing this disruptive innovation and realizing cost reductions. ChemStress will reduce the cost of biological drugs through lower manufacturing costs so enabling EU governments to provide these drugs to EU citizens at a lower cost.


List of deliverables.
CE marked product Demonstrators, pilots, prototypes 2020-02-11 12:50:34
Peer reviewed publication submitted Demonstrators, pilots, prototypes 2020-02-11 12:50:34
Results exchanged Demonstrators, pilots, prototypes 2020-02-11 12:50:34

Take a look to the deliverables list in detail:  detailed list of BIOSIM deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOSIM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOSIM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More